Thomson CompuMark Launches World's Most Comprehensive Trademark Search Offering for Pharmaceutical Brand Owners
New, proprietary sources in Pharmaceutical XC Search reduce the risk of costly brand conflicts
BOSTON, May 26 /PRNewswire/ -- Thomson CompuMark, a Thomson Reuters business, today announced new, proprietary FDA drug sources in its Pharmaceutical XC Search, plus authentic FDA Phonetic Orthographic Computer Analyses (POCAs) of potential marks, both of which reduce the risk of pharmaceutical brand conflicts. This new content comprises the world's most comprehensive coverage of drug-related brands and helps companies protect their investment in creating, clearing and registering drug trademarks.
"With so many drug names on the market, pharmaceutical brand owners face particularly complex challenges when developing new trademarks," said Martin Burke, group managing director of Thomson CompuMark. "Expanding the coverage of our industry-leading Pharmaceutical XC Search is just the latest example of how Thomson Reuters keeps brand owners, and the IP professionals who advise them, ahead of the curve, providing the most complete information to help them make better decisions and reduce their business risk."
Pharmaceutical XC Search offers:
- Exclusive search coverage of Thomson Reuters Micromedex, including international and FDA-approved drugs, as well as the Natural Medicines Database, the gold standard for natural medicines product information
- Additional FDA-recommended sources, including Drugs@FDA, AERS (Adverse Event Reporting System) and VAERS (Vaccine Adverse Event Reporting System) – important sources of brand names for which adverse events have been reported
- An authentic FDA POCA of Thomson CompuMark's proprietary database featuring more than 90,000 drug names – the most extensive in the industry. Endorsed by the FDA, POCAs help clients identify potentially problematical names early in the clearance process, prior to FDA submission, by assessing the similarity of the mark in writing and speech, thereby reducing the risk of name rejection due to potential confusion
- New Citation Matrix showing the incidence of use for researched marks across the sources searched, offering additional insight on trademark use.
For more information on Pharmaceutical XC Search, go to http://compumark.thomson.com/do/pharmaceutical.
About Thomson CompuMark
Thomson CompuMark, a part of Thomson Reuters, delivers comprehensive solutions for global trademark research and brand protection, powered by the most extensive trademark resources in the world. Widely recognized as the global industry leader, Thomson CompuMark currently serves 80 of the top 100 brand owners and many of the world's leading intellectual property law firms.
About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs 55,000 people and operates in over 100 countries. For more information, go to www.thomsonreuters.com.
SOURCE Thomson CompuMark
Share this article